Semra Paydaş, Melek Ergin, Suzan Zorludemir, Yalçın Kekeç, Gürhan Sakman, Orçun Yalav, Emine Bağır Kılıç, Ahmet Gökhan Sarıtaş, İsmail Cem Eray, İsmail Oğuz Kara

Lokal ileri evre meme kanserli hastalarda, neoadjuvan kemoterapinin östrojen reseptörleri, progesterone reseptörleri, Cerb-B2, vasküler endotelyal büyüme faktörü ve Ki-67 üzerine etkisi

Amaç: Bu çalışmada lokal ileri evre meme kanserli hastalarda neoadjuvan kemoterapi ile tümör çapı, tümörlü dokuda çalışılan vasküler endotelyal büyüme faktörü (VEGF), östrojen reseptörü (ER), progesteron reseptörü (PR), Ki-67 ve Cerb-B2 ekspresyonlarındaki değişimin gösterilmesi amaçlanmıştır. Gereç ve Yöntem: Çukurova Üniversitesi Tıp Fakültesi Genel Cerrahi ve Tıbbi Onkoloji Bilim Dalı’nda 2008 ve 2013 yılları arasında lokal ileri meme kanseri nedeniyle tedavi gören 69 hastanın verileri prospektif olarak araştırılmıştır. Tümör çapı, tümörlü dokuda çalışılan VEGF, Ki-67, ER, PR ve Cerb-B2 ekspresyonları immunhistokimyasal (İHK) yöntem ile neoadjuvan kemoterapi öncesi ve sonrası dönemde karşılaştırmalı olarak değerlendirilmiştir. Bulgular: Neoadjuvan kemoterapi sonrası tümör çapı, VEGF, Ki-67, ER, PR ve Cerb-B2 ekspresyonlarında istatistiksel olarak anlamlı düşüş saptandı. Sonuç: Tümör dokusunda çalışılan VEGF düzeyindeki anlamlı düşme, tümörün anjiyogenezinin ve bu yolla metastaz yapabilme yeteneğinin neoadjuvan kemoterapi etkisiyle azalabileceği sonucunu telkin etmektedir. Tümör dokusunda çalışılan Ki-67 proliferasyon indeksinde anlamlı değişim; malign hücre proliferasyonunun neoadjuvan kemoterapi etkisiyle azaldığını gösterebilir.

Effect of neoadjuvant chemotherapy on estrogen receptor, progesterone receptor, Cerb-B2, vascular endothelial growth factor and Ki-67 in patients with locally advanced breast cancer

Purpose: The aim of this study is aimed to demonstratethe changes in the tumor diameter and expressions ofvascular endothelial growth factor (VEGF), estrogenreceptor (ER), progesterone receptor (PR), Ki-67, andCerb-B2 status after neoadjuvant chemotherapy in thepatients with locally advanced breast cancer.Materials and Methods: Sixty-nine patients whodiagnosed with locally advanced breast cancer and treatedwith were prospectively evaluated. The tumor diameterand VEGF, Ki-67, ER, PR, and Cerb-B2 expressionstested by immunohistochemistry (IHC) were evaluatedbefore and after neoadjuvant chemotherapy.Results: There was a statistically significant reduction inthe tumor diameter and in the expression of VEGF, Ki67, ER, PR, and Cerb-B2 after neoadjuvant chemotherapy.Conclusion: The significant reduction in VEGFexpression suggests that the tumor angiogenesis and itsmetastatic ability may be reduced by neoadjuvantchemotherapy. The significant change in the Ki-67proliferation index may suggest the reduced proliferativeactivity of malignant cells with neoadjuvant chemotherapy.

PDF

___

1. Jatoi I. Breast cancer: a systemic or local disease? Am J ClinOncol. 1997;20:536-9.
2. Teshome M, Hunt K, . Neoadjuvant therapy in the treatment of breast cancer. Surg Oncol Clin N Am. 2014;23:505–23.
3. Mieog JS, van der Hage JA, van de Velde CJ. Neoadjuvant chemotherapy for operable breast cancer. Br J Surg. 2007;94:1189-200.
4. Mauri D, Pavlidis N, Ioannidis JP. Neoadjuvant versus adjuvant systemic treatment in breast cancer:a meta-analysis. J Natl Cancer Inst. 2005;97:188–94.
5. Lee MC, Newman LA. Management of patients with locally advanced breast cancer. Surg Clin North Am. 2007;87:379-98.
6. Wolff AC, Davidson NE. Preoperative therapy in breast cancer: lessons from the treatment of locally advanced disease. Oncologist. 2002;7:239-45.
7. Buchholz TA, Hunt KK, Whitman GJ, Sahin AA, Hortobagyi GN. Neoadjuvant chemotherapy for breast carcinoma: multidisciplinary considerations of benefits and risks. Cancer. 2003;98:1150-60.
8. Kuehn T, Bauerfeind I, Fehm T, Fleige B, Hausschild M, Helms G et al . Sentinel-lymph-node biopsy in patients with breast cancer before and after neoadjuvant chemotherapy (SENTINA): a prospective, multicentre cohort study. Lancet Oncol. 2013;14:609-18.
9. Güler N, Karabulut B, Koçdor MA, Kaya H, Esen G, Özaslan C et al. Locally advanced breast cancer2010 Istanbul breast cancer consensus meeting. Journal of Breast Health. 2011:7;68-85.
10. Mamounas EP, Fisher B. Preoperative (neoadjuvant) chemotherapy in patients with breast cancer. Semin Oncol. 2001;28:389–99.
11. Edge SB, Byrd DR, Compton CC, Fritz AG, Grene FI, Trotti A. Breast in AJCC Cancer Staging Manual. Seventh Edition. Chicago, IL, Springer, 2010.
12. Kim EA, Gershtein ES, Vyotskaya IV, Kushlinskii NE. Expression of VEGF and VEGFR2 in tumors during neoadjuvant therapy of patients with breast cancer. Bull Exp Biol Med. 2008;145:245-8.
13. Burcombe RJ, Makris A, Richman PI, Daley FM, Noble S, Pittam M et al. Evaluation of ER, PgR, HER-2 and Ki-67 as predictors of response to neoadjuvant anthracycline chemotherapy for operable breast cancer. Br J Cancer. 2005;92:147-55.
14. Arens N, Bleyl U, Hildenbrand R. HER2/neu, p53, Ki67, and hormone receptors do not change during neoadjuvant chemotherapy in breast cancer. Virchows Arch. 2005;446:489-96
15. Koda M, Sulkowska M, Koda KL et al. The effect of chemotherapy on Ki-67, Bcl-2 and Bak expression in primary tumors and lymph node metastases of breast cancer. Oncol Rep. 2007;18:113-9.
16. Dede DS, Gumuskaya B, Guler G, Onat D, Altundag K, Ozisik Y. Evaluation of changes of biologic markers ER, PR, HER 2 and Ki-67 in breast cancer with administration of neoadjuvant dosedense doxorubicin, cyclophosphamide followed by paclitaxel. J BUON. 2013;18:366-71.
17. Colleoni M, Giuseppe V, David Z. Chemotherapy Is more effective in patients with breast cancer not expressing steroid hormone receptors: a study of preoperative treatment. Clin Cancer Res. 2004:10;6622-8
18. Faneyte IF, Schrama JG, Peterse JL, Remijnse PL, Rodenhuis S, van de Vijver MJ. Breast cancer response to neoadjuvant chemotherapy: predictive markers and relation with outcome. Br J Cancer. 2003;88:406-12.
19. Avci N, Deligonul A, Tolunay S, Cubukcu E , Olmez OF, Ulas A et al. Neoadjuvant chemotherapyinduced changes in immunohistochemical expression of estrogen receptor, progesterone receptor, HER2, and Ki-67 in patients with breast cancer. J BUON. 2015:20:45-9.
20. Kinsella MD, Nassar A, Siddiqui MT, Cohen C. Estrogen receptor (ER), progesterone receptor (PR), and HER2 expression pre- and post- neoadjuvant chemotherapy in primary breast carcinoma: a single institutional experience. Int J Clin Exp Pathol. 2012;5:530-6.
21. Adams AL, Eltoum I, Krontiras H, Wang W, Chhieng DC. The effect of neoadjuvant chemotherapy on histologic grade, hormone receptor status, and HER2/neu status in breast carcinoma. Breast J. 2008;14:141-6.
22. Penault LF, Cayre A, Bouchet MF, Amat S, Feillel V, Le Bouedec G et al.Induction chemotherapy for breast carcinoma: predictive markers and relation with outcome, Int J Oncol. 2003;22:1319-25.
23. Schneider J, Lucas R, Sánchez J, Ruibal A, Tejerina A, Martín M. Modulation of molecular marker expression by induction chemotherapy in locally advanced breast cancer: correlation with the response to therapy and the expression of MDR1 and LRP. Anticancer Res. 2000;20:4373-7.
24. Varga Z, Caduff R, Pestalozzi B. Stability of the HER2 gene after primary chemotherapy in advanced breast. Virchows Arch. 2005;446:136-41.
25. Kaya AO, Büyükberber S, Yamaç D. Changes in hormone receptor and Her2 Status after neoadjuvant chemotherapy in breast cancer. J Med Sci. 2010;30:469
26. Makris A, Powles TJ, Dowsett M, Osborne CK, Trott PA, Fernando IN et al. Prediction of response to neoadjuvant chemoendocrine therapy in primary breast carcinomas. Clin Cancer Res. 1997;3:593-600.
27. Neubauer H, Gall C, Vogel U, Hornung R, Wallwiener D, Solomayer E et al. Changes in tumour biological markers during primary systemic chemotherapy (PST). Anticancer Res. 2008;28:1797- 804.
28. Partridge SC, Gibbs JE, Lu Y, Esserman LJ, Tripathy D, Wolverton DS et al. MRI measurements of breast tumor volume predict response to neoadjuvant chemotherapy and recurrence-free survival. AJR Am J Roentgenol. 2005;184:1774-81.
29. Cortazar P, Zhang L, Untch M et al. Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis. Lancet. 2014;384:164-172.
30. Folkman J. Angiogenesis in cancer, vascular, rheumatoid and other disease. Nat Med. 1995;1:27- 31.
31. Sun B, Song ST, Jiang ZF, Wang T, Zhang SH, Meng XY et al . Analysis of the factors affecting pathologic complete response to neoadjuvant chemotherapy in breast cancer patients. Zhonghua Zhong Liu Za Zhi. 2013;35:38-42.